Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pharmather Hldgs Ltd (CSE:PHRM)

0.3200 UNCHANGED
Streaming Delayed Price Updated: 3:13 PM EDT, Jun 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 225,980
Open 0.3350
Bid (Size) 0.3200 (10,000)
Ask (Size) 0.3550 (2,500)
Prev. Close 0.3200
Today's Range 0.3050 - 0.3400
52wk Range 0.1550 - 0.3650
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PharmaTher Applauds FDA's New Commissioner’s National Priority Voucher (CNPV) Program, Citing Potential to Accelerate its Ketamine Programs for Mental Health, Pain, and Neurological Disorders, and National Security Applications
Provides Accelerated Path to Market for PharmaTher’s Ketamine-based Proprietary Delivery Systems & Orphan Drug Designations, and Leveraging its Ketamine Product, having an FDA Approval Goal Date on... 
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Announces FDA Extends Review Period for Ketamine; New Approval Goal Date August 9, 2025
From PharmaTher Holdings Ltd.
Via GlobeNewswire

Performance

YTD
+39.1%
+39.1%
1 Month
+56.1%
+56.1%
3 Month
+45.5%
+45.5%
6 Month
+42.2%
+42.2%
1 Year
+60.0%
+60.0%

More News

Read More
PharmaTher Unveils KetaVault™: A First-of-Its-Kind Portal to Accelerate Ketamine Research and Commercialization
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Receives US FDA Approval Goal Date for Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Provides Complete Response Amendment for US FDA New Drug Application for Ketamine
Via Newsfile
Exposures Product Safety
PharmaTher Provides Update on FDA New Drug Application for Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher CEO Issues Letter to Shareholders
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Announces Update on FDA New Drug Application for Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Announces Update on FDA New Drug Application for Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Announces Post Complete Response Letter Clarification Meeting Request Granted from the FDA for Ketamine Abbreviated New Drug Application
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke
From Revive Therapeutics Ltd.
Via GlobeNewswire
PharmaTher Receives Complete Response Letter from the U.S. Food and Drug Administration for Ketamine Abbreviated New Drug Application
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Announces Update on FDA New Drug Application for Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
From Revive Therapeutics Ltd.
Via GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Provides Update for Expected FDA Approval of Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX™ (Ketamine)
From PharmaTher Holdings Ltd.
Via GlobeNewswire

Frequently Asked Questions

Is Pharmather Hldgs Ltd publicly traded?
Yes, Pharmather Hldgs Ltd is publicly traded.
What exchange does Pharmather Hldgs Ltd trade on?
Pharmather Hldgs Ltd trades on the Canadian Securities Exchange
What is the ticker symbol for Pharmather Hldgs Ltd?
The ticker symbol for Pharmather Hldgs Ltd is PHRM on the Canadian Securities Exchange
What is the current price of Pharmather Hldgs Ltd?
The current price of Pharmather Hldgs Ltd is 0.3200
When was Pharmather Hldgs Ltd last traded?
The last trade of Pharmather Hldgs Ltd was at 06/23/25 03:13 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.